摘要
目的探讨甲状腺乳头状癌中CD44v6、BRAF和Rasp21的表达,及其与淋巴结转移的关系。方法应用免疫组化SP法,对38例有颈淋巴结转移的甲状腺乳头状癌(PTC+LNM)患者、22例甲状腺乳头状癌但无颈部淋巴结转移患者和50例甲状腺腺瘤(TA)患者组织中的CD44v6、BRAF和Rasp21进行检测。结果有淋巴结转移组(PTC+LNM)的CD44v6、BRAF和Rasp21阳性率显著高于无淋巴结转移组(PTC)和甲状腺腺瘤(TA)组(P<0.05)。结论 CD44v6、BRAF和Rasp21的阳性表达与甲状腺乳头状癌的颈淋巴结转移密切相关,可作为甲状腺乳头状癌较好的转移及预后评估指标。
Objective To investigate the expression of CD44v6,BRAF and Rasp21 in thyroid carcinoma and investigate their relationship with lymph node metastasis. Methods The expression of CD44v6 ,BRAF and Rasp21 was decected with immunohistochemical SP method in 60 cases of papillary thy- roid carcinoma （PTC） 38 cases a neck curry favor with lymph node metastasis （ PTC ＋ LNM）, 22 cases of no neck curry favor with lymph node metastasis （PTC）） and 50 case of thyroid adenoma （TA）. Results The PTC ＋ LNM group CD44v6,BRAF and Rasp21 were significantly higher than PTC and TA group （P 〈 0. 05）. Conclusions There was a close relationship between CD44v6,BRAF and Rasp21 posi- tive expression and papillary thyroid carcinoma neck lymph node metastasis. ;CD44v6,BRAF and Rasp21 can be as a good catch papillary thyroid carcinoma metastases, prognostic index.
出处
《中国肿瘤临床与康复》
2012年第4期310-312,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
